With the deep analysis of the above alternatives, it is recommended that the company ought to select the alternative 3 in order to preserve a competitive position in the long run. As the alternative 3 would enable the business to not just introduce brand-new and innovative products in the market it would also minimize the high expenses on R&D under alternative 2 and increase the revenue margins. It would allow the business to increase its share costs too, as investors are willing to invest more in business with substantial R&D spending and increase in the total worth of the company.
Action and implementation Strategy
Strategy can be implemented successfully by developing certain short-term in addition to long term plans. These strategies might be as follows;
Short Term Plan (0-1 year)
• Under the short term strategy Genzyme The Synvisc One Investment Decision must perform various activities to execute its NHW technique efficiently. These activities are as follows;.
• Get the audit of its brand portfolio done, to analyze the core selling brand names, which generate most of its revenue.
• Analyze the current target audience as well as the market section which is not include in the business's circle.
• Examine the existing financial data to measure the amount that should be invested in the R&D and acquisitions.
• Analyze the possible financiers and their nature, i.e. do they want long term benefits (capital gain), or the want early earnings (dividend). It would let the business to understand that how much amount must be spent on R&D.
Mid Term Plan (1-5 years)
• Obtain those organizations in which the company has potential experience to deal with. Acquire most favorable companies with a strong commitment to health, to develop the customer's understandings in the best direction.
• Focus more on acquisitions than R&D to construct the base in the customer's mind about Genzyme The Synvisc One Investment Decision worths and vision and to avoid potential danger of sunk expense.
Long Term Plan (1-10 years)
• Acquire companies with health along with taste aspect, as the base for the Genzyme The Synvisc One Investment Decision as a business producing healthy items has been constructed under midterm strategy and now the company could move towards taste factor too to comprehend the consumers, which focus more on taste instead of health.
• Be more aggressive towards R&D than the acquisitions, as it is the substantial time to construct brand-new products.
